By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


National Institute of Allergy And Infectious Diseases (NIAID) 

31 Center Drive MSC 2520
Building 31, Room 7A-50
Bethesda  Maryland  20892-2520  U.S.A.
Phone: 301-496-5717 Fax:




MedImmune, LLC 


Company News
Geom Therapeutics Announces Agreement With NIAID For Clinical Advancement Of GT-1 9/13/2017 6:25:53 AM
Zavante Therapeutics Announces Agreement With NIAID To Assess ZOLYD For Lower Respiratory Tract Infections 9/8/2017 6:35:49 AM
Soligenix (SNGX) Receives $2.5M In Additional NIAID Funding To Advance Development Of Heat Stable Ricin Vaccine 8/14/2017 6:54:40 AM
Soligenix (SNGX) Receives Additional NIAID Funding To Advance Development Of Heat Stable Ricin Vaccine 6/21/2017 8:30:40 AM
MaxCyte And NIAID To Collaborate On Research For Ultra-Rare Disease Therapy 6/6/2017 8:17:42 AM
Matinas BioPharma And NIH/NIAID Initiate Open-Label Extension To Phase IIa Study Of MAT2203 In Chronic Mucocutaneous Candidiasis 3/6/2017 10:34:15 AM
MRIGlobal Wins $13.7M NIH/NIAID Quality Assessment Contract For Mycobacterium Tuberculosis 2/1/2017 9:44:45 AM
Paragon Bioservices Release: NIAID Awards Company A Multiple Award IDIQ Contract Valued Up To $159 Million For Preclinical Drug Development Services 1/18/2017 8:04:36 AM
MaxCyte, Inc. Release: Company, NIH NIAID Study Published In Science Translational Medicine Demonstrates CRISPR-Cas9 Repair Of X-Linked Chronic Granulomatous Disease (CGD) Gene 1/12/2017 7:31:14 AM
CSRA's DynPort Vaccine Company LLC To Help Advance Medical Products For The NIAID 12/27/2016 10:59:06 AM